AI healthcare company Forus has raised $150 million in Series C financing, bringing its valuation to $3 billion as the company expands its artificial intelligence-powered healthcare network designed to help connect physicians, patients, pharmacies, insurers and biopharmaceutical companies.
The latest financing marks a significant increase in Forus’ valuation. The company has tripled its valuation in approximately four months, highlighting growing investor interest in AI applications that address operational and access-related challenges across healthcare.
The latest round brings Forus’ total funding to more than $300 million, providing the company with additional capital to expand its technology, healthcare network and presence across medical specialties and care settings.
Bain Capital Ventures led the Series C financing, while existing investors also participated in the round. The continued participation of previous backers highlights sustained investor confidence in Forus’ approach to applying AI to healthcare access and medication-related workflows.
Forus Targets the Gap Between Prescription and Treatment
Forus is focused on one of the less visible challenges in healthcare: the administrative and logistical barriers that can prevent patients from beginning treatment after a physician has prescribed a medication.
A prescription does not always translate into immediate treatment. Insurance authorization, financial assistance, pharmacy selection, medication availability and other administrative requirements can create delays for patients while adding workload for medical practices.
Forus uses AI agents to manage activities between the prescribing decision and the patient’s start of treatment. According to the company, its platform is designed to navigate insurance requirements, financial assistance and pharmacy-related processes across medications, payers and pharmacies.
The company’s approach assigns an AI agent to each prescription and uses relevant information to help determine the steps required to move the prescription forward.
This positions Forus not simply as an AI software provider but as a technology layer designed to connect different participants involved in the medication-access process.
Platform Reaches All 50 U.S. States
Forus has expanded its network across all 50 U.S. states, according to information released by the company. Its platform reportedly reaches patients across approximately 85% of U.S. residential ZIP codes.
The company has also expanded adoption among healthcare providers, with more than one-third of providers in its initial specialty using the platform.
Forus is also working with nine of the world’s 15 largest biopharmaceutical companies, demonstrating the company’s effort to build relationships beyond individual physician practices and into the pharmaceutical sector.
The geographic scale of the network could allow Forus to identify recurring operational barriers across prescription and treatment journeys. These insights may help healthcare providers and pharmaceutical companies better understand where patients encounter difficulties in accessing prescribed therapies.
New Funding to Support Broader Healthcare Expansion
The new $150 million Series C financing is expected to support Forus’ expansion into additional medical specialties and healthcare settings.
The company plans to broaden the capabilities of its AI agents and increase its ability to manage additional stages of the treatment journey. The funding is also expected to support workforce expansion and continued development of the company’s technology infrastructure.
Forus’ longer-term objective is to establish its platform more broadly across the U.S. healthcare system rather than limiting its services to a particular specialty or group of medicines.
Founder and CEO Sahir Jaggi has said the company aims to bring its platform into doctors’ offices across the country, with a focus on helping medical advances reach patients more efficiently.
From Tandem to Forus
Forus was previously known as Tandem before adopting the Forus name earlier in 2026.
The company’s fundraising momentum has accelerated rapidly. It raised more than $160 million in May, followed by the latest $150 million Series C financing.
The rapid increase in capital reflects a broader shift in healthcare technology investment toward AI applications designed to address practical operational problems.
While much of the attention surrounding healthcare AI has focused on diagnosis, clinical decision support and drug discovery, companies such as Forus are targeting processes that occur around the delivery of care.
AI Moves Beyond Clinical Applications
Artificial intelligence in healthcare is increasingly being applied to areas surrounding patient care, including administration, insurance processes, workflow management, medication access and patient engagement.
Forus’ business model illustrates how AI can potentially coordinate fragmented processes involving multiple organizations. A physician may prescribe a medicine, but the patient’s ability to obtain it can depend on insurance requirements, affordability, pharmacy availability and other factors.
By attempting to automate these steps, Forus is targeting a problem that sits between clinical decision-making and actual treatment.
Forus’ Position Within the Expanding AI Healthcare Market
The growth of the AI in healthcare market creates a larger addressable environment for companies developing AI-powered healthcare infrastructure.
Forus is targeting a specific part of this ecosystem: the connection between prescription, medication access and treatment initiation.
Its network-based approach could become increasingly relevant as healthcare systems look for ways to reduce administrative workloads and improve patient access to therapies.
For pharmaceutical companies, the platform may also provide insights into where patients encounter barriers after medications are prescribed. Understanding these obstacles can be important for companies introducing therapies that involve complex insurance, reimbursement or patient-support processes.
The company’s strategy therefore extends beyond providing an AI application to an individual healthcare organization. It is attempting to build a network that connects multiple stakeholders involved in the medication journey.
What the $3 Billion Valuation Signals
Forus’ latest valuation highlights investor interest in AI-enabled healthcare infrastructure.
The company’s valuation has increased approximately threefold in about four months, making the latest financing notable not only for the amount raised but also for the speed of the valuation increase.
The financing also reflects growing investor interest in healthcare AI companies that can demonstrate applications beyond experimental technology.
However, the long-term significance of the $3 billion valuation will depend on Forus’ ability to convert its expanding network into sustainable adoption, measurable healthcare outcomes and a scalable business model.
Healthcare AI companies also face significant challenges. These include integrating technology into existing clinical workflows, protecting sensitive patient information, maintaining reliable AI performance and navigating complex healthcare reimbursement and insurance systems.
Forus’ strategy therefore depends on combining AI capabilities with healthcare infrastructure, provider relationships and operational expertise.
AI and the Changing Healthcare Delivery Model
The expansion of companies such as Forus reflects a broader evolution in how artificial intelligence is being deployed across healthcare.
Early healthcare AI applications frequently centered on areas such as medical imaging, clinical decision support and predictive analytics. Increasingly, AI is being used to automate administrative processes and coordinate interactions among patients, providers, insurers, pharmacies and pharmaceutical companies.
This shift could become particularly important as healthcare organizations face pressure to control costs while improving access and patient experiences.
According to the Medi-Tech Insights outlook, the projected 34–36% growth in the global AI in healthcare market from 2024 to 2029 reflects the increasing adoption of AI across multiple healthcare functions.
Forus represents one example of this broader trend, focusing on medication access rather than directly replacing clinical decision-making.
The Road Ahead for Forus
With more than $300 million in total funding and a network covering all 50 U.S. states, Forus enters its next stage with ambitions to expand across specialties and healthcare settings.
The company’s priorities include increasing adoption among healthcare providers, expanding the capabilities of its AI agents and strengthening relationships across the healthcare ecosystem.
The latest financing also provides Forus with additional resources to compete in an increasingly crowded healthcare AI market.
For investors, the funding round represents a bet that AI can become an important component of healthcare infrastructure. Forus, meanwhile, is attempting to address a practical problem: reducing the distance between a physician prescribing a treatment and a patient actually receiving it.
If the company can continue expanding its network while maintaining reliability, security and trust among physicians, patients, payers, pharmacies and pharmaceutical companies, its latest financing could position Forus as an important participant in the emerging AI-enabled healthcare infrastructure market.
Key Facts About the Forus Funding
| Metric | Details |
| Company | Forus |
| Latest funding | $150 million |
| Funding round | Series C |
| Valuation | $3 billion |
| Lead investor | Bain Capital Ventures |
| Total funding | More than $300 million |
| Geographic coverage | All 50 U.S. states |
| Patient reach | Approximately 85% of U.S. residential ZIP codes |
| Biopharma relationships | 9 of the world’s 15 largest biopharmaceutical companies |
| Previous company name | Tandem |
| Market context | Global AI in healthcare market expected to grow 34–36% from 2024 to 2029, according to Medi-Tech Insights |
Reference
Reuters — Forus AI healthcare platform valued at $3 billion
Forus — $150M Series C at $3B valuation
Business Wire — Forus Raises $150M at a $3B Valuation
Tech Funding News — Forus $150M funding and $3B valuation
Yahoo Finance — Forus healthcare funding coverage
Jeff Berman is a healthcare and medical technology journalist with over 7 years of experience covering the global medtech, biotechnology, pharmaceutical, and healthcare sectors. As a contributor to Just MedTech, he specializes in industry news, market trends, regulatory developments, mergers and acquisitions, and emerging innovations shaping the future of healthcare worldwide. Contact: jeff.b@justmedtech.com.